4 Drug Stocks Poised To Beat This Earnings Season
Zacks Investment Research | May 08, 2017 05:24AM ET
This earnings season started on a promising note for the pharma/biotech sector after a challenging 2016. The sector has been going through a rough patch due to media and political focus on steep drug pricing issues. Interestingly, the NASDAQ Biotechnology Index (^NBI) and the NYSE ARCA Pharmaceutical Index (^DRG) gained 9.4% and 6.2%, respectively so far in the year, reflecting the strong start witnessed by the sector.
M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017. Investors will also be glued to new product approvals along with label expansion of existing drugs and regular pipeline updates for key drugs.
Factors Influencing the Quarter
With the earnings season drawing to a close and majority of the bigwigs having reported results we can conclude that the pharma/healthcare sector has witnessed a mixed performance.
Industry bellwether Johnson & Johnson (NYSE:JNJ) (Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.